It may also partly explain the efficacy of apremilast, as this agent reduces inflammatory cytokine release and increases anti-inflammatory cytokine production in response to IL-17 stimulation in psoriasis [46–48], and IL-17A is a biomarker of apremilast efficacy in psoriasis [49]. The gene discussed is IL17A; the disease is psoriasis.